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Acute  coronary  syndromes  secondary  to allergy-induced  coronary  vasospasm  are  known  as  “Kounis  syn-
drome.”  The  main  pathophysiological  mechanism  of  coronary  spasm  in  Kounis  syndrome  is  the release  of
inﬂammatory  mediators  during  a hypersensitivity  reaction  triggered  by food, insect  bites,  or drugs.  Here,
we  report  a  case  of an  acute  coronary  syndrome  secondary  to allergic  reaction  following  levoﬂoxacin
administration  in  a 68-year-old  female  without  a  prior  history  of  coronary  artery  disease.  Our  patient’s
coronary  angiography  revealed  moderate  lesions  in the  coronary  vasculature  and she was  diagnosed  as
having a  type  II variant  Kounis  syndrome.  Type  II variant  includes  patients  in  whom  the acute  release  of
inﬂammatory  mediators  due  to mast  cell  degranulation  such  as histamine,  serotonin,  and  leukotrienes
can  induce  either  coronary  artery  spasm  with  normal  cardiac  enzymes  and  troponins  or plaque  erosion
or  rupture  manifesting  as  acute  myocardial  infarction.  According  to our knowledge,  this  is  the  ﬁrst  case
report  of Kounis  syndrome  attributed  to  levoﬂoxacin  administration.
<Learning  objective:  Kounis  syndrome  is  an established  entity  that  describes  the  triggering  of  an  acute
coronary  syndrome  by an  allergic  reaction.  This  is  the  ﬁrst case  report  of Kounis  syndrome  attributed  to
levoﬂoxacin  administration.  We  reviewed  the  literature  and  present  the  pathophysiologic  mechanism  of
Kounis  syndrome.>
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Kounis syndrome is the coincidental occurrence of an acute
oronary syndrome (ACS) with hypersensitivity reactions involv-
ng activation of interrelated and interacting inﬂammatory cells
nd including allergic or hypersensitivity and anaphylactic or ana-
hylactoid insults [1]. It is caused by inﬂammatory mediators
uch as histamine, neutral proteases, arachidonic acid products,
latelet activating factor, and a variety of cytokines and chemokines
eleased during the hypersensitivity insult [2–5]. Type II variant
ncludes patients with culprit but quiescent pre-existing atheroma-
ous disease in whom the acute release of inﬂammatory mediators
an induce either coronary artery spasm with normal cardiac
nzymes and troponins or plaque erosion or rupture manifesting
s acute myocardial infarction. Here, we report a case of an ACS in a
atient with systemic immediate hypersensitivity reaction which
eveloped following oral administration of levoﬂoxacin.
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Case report
A 68-year-old woman, hypertensive, diabetic, and hyperlipi-
demic was admitted to our hospital with retrosternal chest pain,
dyspnea, nausea, and vomiting of 1 h duration after taking a
dose of levoﬂoxacin due to erysipelas of the left lower limb. Her
physical examination revealed a blood pressure and heart rate of
120/75 mmHg  and 95 bpm, respectively, and generalized erythema
and urticarial rashes. Heart and respiratory auscultation ﬁndings
were normal. The electrocardiogram (ECG) showed ST depression
in V3–V5 leads (Fig. 1a and b). The patient was  treated with supple-
mental oxygen, intravenous methylprednisolone 40 mg  along with
nebulized albuterol and intravenous nitroglycerin infusion. Anti-
ischemic treatment including aspirin, clopidogrel, beta-blocker,
statin, as well as angiotensin-converting enzyme inhibitor were
initiated. The patient showed prompt response to the therapy, and
signs and symptoms of allergic reaction resolved in a couple of
hours. Signs of ischemia and the ECG changes disappeared along
with the signs of allergic reaction. Troponin I was elevated up to
1.3 ng/ml. Creatine phosphokinase and creatine kinase-MB values
were elevated up to 550 U/l and 90 U/l, respectively. Blood tests
showed moderate eosinophilia in her peripheral blood smear (10%)
while the measurements of non-speciﬁc total immunoglobulin
vier Ltd. All rights reserved.
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 levels were increased up to 500 UI/ml. Coronary angiography
hich was performed 24 h later, revealed 50–60% stenosis of the
id  left anterior descending artery (LAD), a 70% ostial lesion of the
ircumﬂex (LCx), as well as a 60% lesion in the mid  right coronary
rtery (RCA) (Fig. 2a–c). A three-vessel fractional ﬂow reserve
FFR) test was performed which revealed non-signiﬁcant lesions in
he LAD (FFR = 0.83) and RCA (FFR = 0.88) and a haemodynamically
ig. 2. Coronary angiography of the left coronary artery (panel a and b) and right coron
eferences to color in this ﬁgure legend, the reader is referred to the web  version of this alescence (panel b). ST depression is indicated with red arrows.
signiﬁcant lesion in the ostial LCx (FFR = 0.74). On the basis of FFR
measurements a percutaneous coronary intervention of the LCx
was proposed which was  refused by the patient. The echocardio-
graphic study of the patient revealed left ventricular hypertrophy
with preserved function without segmental motility abnormalities.
The rest of her hospitalization was  without any complications.
She was discharged on the 7th day of hospitalization.
ary artery (panel c). Lesions are indicated with red arrows. (For interpretation of
rticle.)
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Kounis syndrome has been deﬁned as an ACS that manifests
s vasospastic angina or ST-elevation myocardial infarction/non-
T-elevation myocardial infarction triggered by the release of
nﬂammatory mediators following an allergic insult [2]. The mech-
nisms of this syndrome are characterized by coronary artery
asospasm due to mast cell degranulation and the subsequent
elease of vasoactive mediators [3]. The most important vasoactive
ediators responsible for coronary artery spasm and consequences
f Kounis syndrome are histamine, serotonin, and leukotrienes.
here are two variants of Kounis syndrome [1–5]. The ﬁrst is
bserved in patients with no cardiovascular risk factors and
ealthy coronary arteries in which the inﬂammatory cascade
riggered by the allergic insult causes a coronary vasospasm
ccompanied by elevated or normal levels of cardiac enzymes.
he second is observed in patients with pre-existing athero-
atous disease (whether known or not) in whom the release
f these mediators would also produce a coronary vasospasm,
hich occurs with normal cardiac enzymes or rupture of the
theromatous plaque, manifesting as an acute myocardial infarc-
ion [5–9]. Our patient’s coronary angiography revealed moderate
esions in the coronary vasculature and was diagnosed with a
ype 2 variant. According to our knowledge, this is the ﬁrst case
eport of Kounis syndrome attributed to levoﬂoxacin administra-
ion.
Causes of Kounis syndrome include drugs (antibiotics, anal-
esics, antineoplastics, contrast media, corticosteroids, intravenous
nesthetics, non-steroidal anti-inﬂammatory drugs, skin dis-
nfectants, thrombolytics, anticoagulants), various conditions
angio-edema, bronchial asthma, urticaria, food allergy, exercise-
nduced allergy, mastocytosis, serum sickness), and environmental
xposures (stings of ants, bees, wasps, jellyﬁsh, grass cutting, mil-
et allergy, poison ivy, latex contact, shellﬁsh eating, viper venom
oisoning) [9].
Although there are no deﬁnite diagnostic criteria to differenti-
te Prinzmetal angina from Kounis syndrome, a patient presenting
ith signs and symptoms of a systemic allergic reaction associ-
ted with clinical, laboratory and electrocardiographic ﬁndings of
cute myocardial ischemia should be diagnosed as having Kounis
yndrome [1,2].
The management of patients with Kounis syndrome differs from
hose for non-allergic common ACS [7]. These patients need treat-
ent with steroids, antihistamines, ﬂuid replacement, possibly
pinephrine, oxygen, and antithrombotics before transfer to the
ardiac catheterization laboratory. The treatment should be both
reating coronary lesions and suppressing the allergic reaction.
asodilator drugs, including nitrates and calcium-channel block-
rs, should be considered as a ﬁrst-line therapy since vasospasm
s the primary mechanism [7]. However the utilization of some
[
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drugs is controversial due to the underlying anaphylactic reac-
tion. Acetylsalicylic acid, a ﬁrst-line drug for ACS, may  itself cause
allergic reactions and induce anaphylaxis [2]. Aspirin is among
the most frequent causes of drug-associated anaphylactic reac-
tions [2]. Therefore, the safety of aspirin in patients with Kounis
syndrome is unknown regarding the potential risk of aggravating
an ongoing anaphylactic reaction [2]. Both fractionated and low-
molecular-weight heparins are derived from animals which are
potentially antigenic and can cause allergic reactions. Beta-blockers
may  also offset some of the beneﬁcial effects of epinephrine, which
is the mainstay of treatment of anaphylaxis. Epinephrine is a life-
saving medication in anaphylaxis, however it can aggravate the
ischemia, and induce coronary vasospasm and arrhythmias. There-
fore, given a narrow therapeutic window, the recommended dose
is 0.2–0.5 mg  of intramuscular injection [7].
Anti-ischemic treatment including aspirin, clopidogrel, beta-
blocker, nitrates, statin, as well as angiotensin-converting enzyme
inhibitor were initiated. Corticosteroids are agents playing a major
role in the treatment of allergic reactions, but they are well known
to impair wound healing and scar formation which may cause
myocardial wall thinning, cardiac aneurysms, and wall rupture
[10,11]. Successful use of corticosteroids in allergic ACS has been
reported, and is thus probably safe and appropriate.
The Kounis syndrome is probably not an uncommon disease but,
rather, an underdiagnosed one. Regarding the complex course of
ACS associated with allergic reactions, high awareness, rapid diag-
nosis, and appropriate treatment are of utmost importance.
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